We previously blogged about ViiV Healthcare’s ($GSK) patent lawsuit against Gilead ($GILD) when the case commenced in February 2018. In the case, ViiV alleges that Gilead’s Biktarvy® infringes ViiV’s ‘385 patent. The case is heading for trial in late 2020. Before that, however, Gilead has moved to dismiss the case outright before trial. Will Gilead succeed? Whether or not Gilead’s motion is granted, the issues outlined below will likely form the crux of the dispositive issues in dispute.
Read MoreGilead’s new HIV drug, Biktarvy®, has received FDA approval. Almost immediately, Gilead was hit with a patent-infringement lawsuit by ViiV Healthcare, which is owned by GSK, along with Pfizer and Shionogi. What is Gilead’s exposure?
Read More